report_pricing

Quarterly Report: January-March 2018

£195.00

One Report

Contents: Agomelatine, Apremilast, Azilsartan, Baricitinib, Belinostat, Belinostat, Betrixaban, Bilastine, Brexpiprazole, Brivaracetam, Budesonide, Canagliflozin, Carfilzomib, Carfilzomib, Carfilzomib, Cariprazine, Cetilistat, Crisaborole, Cyclizine, Daclatasvir, Dapagliflozin, Dapagliflozin, Dapagliflozin, Darunavir, Dexmethylphenidate, Diosmin, Dolutegravir, Edoxaban, Edoxaban, Efinaconazole, Eluxadoline, Eluxadoline, Eluxadoline, Ertugliflozin, Ertugliflozin, Flunisolide, Fluocinolone acetonide, Fluocinonide, Glycopyrronium bromide, Hydrocodone, Hydromorphone, Isosulfan blue, Lapatinib, Lesinurad, Linezolid, Meropenem, Methionine, Methylphenidate, Mirabegron, Nebivolol, Neratinib, Obeticholic acid, Obeticholic acid, Obeticholic acid, Olaparib, Omacetaxine mepesuccinate, Oxycodone, Palbociclib, Palbociclib, Permethrin, Pirfenidone, Pregabalin, Ribociclib, Rivaroxaban, Ruxolitinib, Sacubitril, Sacubitril, Saxagliptin, Selexipag, Selexipag, Selexipag, Sofosbuvir, Sofosbuvir, Sofosbuvir, Sofosbuvir, Sofosbuvir, Tiotropium bromide, Tofacitinib, Vemurafenib, Venetoclax, Vildagliptin

SKU: tcipatent-r-0103-2018 Category: Tag:

Reviews

There are no reviews yet.

Be the first to review “Quarterly Report: January-March 2018”

What is a Claimed Intermediate?
A Claimed Intermediate is here defined as a novel pharmaceutical process intermediate which is preferably highly stable, highly isolatable, highly purifiable (optionally with appropriate chirality) and claimed as a compound in a pharmaceutical process patent specification from which it may be subject to a 20 year patent protection term.